Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin liposomal (The Liposome Company)
- Development stage
- Approved
- Lead developer
- Perrigo
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Untargeted liposomal doxorubicin refers to formulations of the anthracycline chemotherapeutic agent doxorubicin encapsulated within liposomes without any active targeting ligands on their surface. This category includes pegylated liposomal doxorubicin (such as Doxil or Caelyx) and non-pegylated liposomal doxorubicin (such as Myocet). Encapsulation within liposomes alters the pharmacokinetic profile of doxorubicin, significantly extending its circulation half-life and promoting accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. This passive targeting mechanism reduces the exposure of healthy tissues, particularly the myocardium, thereby mitigating the cumulative cardiotoxicity associated with conventional free doxorubicin. Untargeted liposomal doxorubicin is widely approved and utilized in the treatment of various malignancies, including ovarian cancer, metastatic breast cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma.
- Brand names
- CaelyxCeldoxomeDoxilLipodoxMyocetZolsketil
- Other names
- doxorubicin liposomaldoxorubicin pegylated liposomalliposomal doxorubicinnon-pegylated liposomal doxorubicinpegylated liposomal doxorubicinuntargeted liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin liposomal (The Liposome Company).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin liposomal (The Liposome Company).